Hanmi Pharmaceutical has begun to conduct the insulin,optimized to administer once a week, for the first time in the world

Published: 2015-02-16 13:46:26

Updated: 2015-02-16 13:46:26

The global Phase 1 clinical trial for the new long-acting basal insulin optimized forpatients to administer once a week has begun.

Hanmi Pharmaceutical (CEO Kwan-soon Lee)recently announced to precedethe Phase 1 clinical trial for LAPSInsulin115 in the U.S., targeting 96patients withtype 1 and 2 diabetes.

The clinical trial conducted in the states will assess safety and drug tolerance of LAPS...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.